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mm. GAIT patients who did not experience OA flare, defined
as increases of (a) 15 mm in WOMAC walking pain and (b)
Likert Physician Global of Disease Severity ≥1, between screen-
ing and randomization visits had a lower placebo response rate
and may have improved ability to discriminate among treatment
groups. Response was defined as 20% improvement in summed
WOMAC Pain between randomization and 6 months of treatment,
and by OMERACT-OARSI criteria. This abstract reports differ-
ences noted in chondroitin sulfate response in these "non-flare"
patients.
Results: Results: 1583 patients were recruited to GAIT. 1221
patients (77.1%) did not have flare as defined above. While
these patients were demographically similar to the overall group,
it was noted that chondroitin sulfate response seemed more pro-
nounced in the non-flare patients that may have less advanced
disease (WOMAC Pain 125-300mm; KL Grade 2) as detailed
below:
20% WOMAC Pain Response
G CS G+CS CE PL
WOMAC Pain =300mm 64.9% 66.7% 60.5% 68.8% 59.4%
WOMAC Pain 301-400mm 63.3% 54.5% 79.2% 69.0% 49.0%
KL Grade 2 65.4% 72.9% 68.5% 74.0% 60.6%
KL Grade 3 63.4% 53.6% 60.5% 61.4% 52.8%
OMERACT-OARSI Response
G CS G+CS CE PL
WOMAC Pain =300mm 59.5% 64.3% 61.0% 65.9% 56.1%
WOMAC Pain 301-400mm 63.3% 52.3% 73.6% 69.0% 43.1%
KL Grade 2 60.2% 70.8% 69.4% 69.9% 56.8%
KL Grade 3 60.4% 50.9% 58.1% 61.4% 49.1%
Conclusions: There may be a differential pain response in GAIT
patients with features that suggest relatively milder OA. The
effect of chondroitin sulfate on OA symptoms may be more pro-
nounced in these patients. Further understanding of the biologic
mechanisms of these agents is necessary.
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DOES THE CORRECTION OF FLEXED POSITION AND
LATERAL DEVIATION USING A SPLINT PROVIDE
THERAPEUTIC ADVANTAGE FOR PATIENTS WITH
OSTEOARTHRITIS OF THE DISTAL INTERPHALANGEAL
JOINTS?
Y. Toda, N. Tsukimura
Toda Orthopedic Rheumatology Clinic, Osaka, Japan
Purpose: Although symptomatic and radiographic osteoarthritis
(OA) of the distal interphalangeal (DIP) joints are common,
there have been few reports concerning the correction of flexed
position and lateral (ulnar or radial) deviation using a splint. We
modified 5-sting banjo finger picks made from tin to correct the
alignment of distal phalanges (the realignment splint) for the
patients with early-phase DIP OA.
Methods: The setting was an Outpatient clinic. Fifty-two patients
with a complaint of DIP joint pain at the single finger and Kellgren
and Lawrence radiographic grade of 2 or 3 at the painful DIP joint
were prospectively randomized and divided into three groups, a
group treated with the realignment splint (n=18), a group with a
placebo splint (n=17), or a group without a splint (n=17). The trial
lasted 4 weeks. The remission scores for the daily activity in the
Australian/Canadian (AUSCAN) Index and the visual analogue
scale (VAS) for subjective DIP joint pain were compared among
the three groups at the conclusion.
Results: The AUSCAN Index at the final assessment showed
significantly greater improvement in the realignment splint group
than in the no splint (p=0.024) and placebo splint (p=0.01)
groups. Similarly, there were significant differences in the change
of VAS between the no splint and realignment splint groups
(p=0.043), and between the realignment and placebo splint
groups (p=0.013).
Fig. 1. The realignment splint.
Conclusions: Through such studies, it will be meaningful to
develop an efficacious splint for patients with hand OA to im-
prove the quality of life while simultaneously reducing costs and
complications.
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Purpose: To assess the influence of patient preference on out-
come in an RCT of intra-articular corticosteroid (IS) and tidal
irrigation (TI) in patients with knee osteoarthritis (OA) and to
identify predictors of patient preference.
Methods: A 6 month, randomised, single blind, parallel group,
clinical trial of patients recruited from Rheumatology clinics with
symptomatic knee OA. Patients were randomised to IS with
40mg triamcinolone acetonide and 2mls of 1% lignocaine or TI
irrigating the knee with 500-1000 mls of normal saline through
a 3 mm diameter trochar. The primary outcome measure for
this analysis was change in WOMAC pain score (VAS). Before
randomization, patients were asked if they had a treatment
preference and this was categorised into: no preference (NP),
received their preference (RP) or did not receive their preference
(NRP). The response to intervention was compared across the
three groups and baseline characteristics were also explored.
Results: 150 subjects were randomised (65% women) and there
were 22 drop-outs (11 in each treatment arm). 79 patients
received IS and 71 TI. The numbers in each preference group
were: RP 44, NRP 60, NP 46. Patients with NP and RP had
significantly greater improvements at 24 weeks compared to
the NRP groups (Figure 1). The NRP patients did not achieve
any benefit at 24 weeks compared to baseline. The greatest
improvements were in those with NP and who received TI, the
worst outcome in those who preferred TI but received IS.
There was no difference between the three groups in clinical
characteristics including age, BMI, duration of disease, presence
of bilateral disease, radiographic severity, presence of effusions
or baseline WOMAC score. Baseline anxiety and depression
scores (HAD) were not different between the 3 groups, neither
was their rating of helplessness using a validated questionnaire.
Women were more likely to express a treatment preference
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than men (75.5% vs 57.7%) and through randomisation got
their preference more often (48.7% vs. 26.7%, p 0.04). The
effects of patient preference on outcome was similar in men
and women, furthermore the overall results of this study were
independent of gender. Patients who had previously received an
IS were more likely to express a preference (83.1% vs. 60.4%,
p=0.003), but were less likely to receive it (32.7% vs. 50.9%,
p=0.002). Adjusting for previous intra-articular injections did not
significantly affect the overall results.
Conclusions: In this study, which demonstrated significant im-
provements for TI compared to IS, patient preference was also
a strong independent predictor of outcome. Those who did not
express a treatment preference obtained the best outcome and
those did not receive their preference did not benefit from the
treatments given. Previous studies suggesting that patient pref-
erence influences outcome have been conducted on treatments
with long term therapies and as such differences have been
attributed to adherence with treatment. This study of a single
baseline intervention suggests that compliance is not the only
reason and hence these findings have major implications for
clinical practice and for the design of future RCT’s.
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RETENTION ON TREATMENT WITH LUMIRACOXIB IN
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Purpose: Retention on treatment reflects the interrelated issues
of efficacy, safety and tolerability in OA patients. Objective: To
show that lumiracoxib 100 mg od and 100 mg bid are non-inferior
to celecoxib 200 mg od with respect to the retention rate at week
52 in patients with OA.
P302 – Table 1
Population treatment group N Retention rate Contrasts Estimated 97.5% CI Outcome
n (%) difference of difference
ITT
LUM 100mg od 755 354 (46.9) LUM 100mg od - CEL 200mg od 0.02 -0.04, 0.07 Non-inferiority shown
LUM 100mg bid 1519 722 (47.5) LUM 100mg bid - CEL 200mg od 0.02 -0.03, 0.07 Non-inferiority shown
CEL 200mg od 758 343 (45.3)
LUM = lumiracoxib; CEL = celecoxib.
Methods: In this 52 week, randomized, double-blind trial, 3036
patients with OA of the hip, knee, hand or spine were ran-
domized to lumiracoxib 100 mg od, lumiracoxib 100 mg bid (2x
recommended dose for OA) and celecoxib 200 mg od in a 1:2:1
ratio.
The primary efficacy variable was the retention rate at 52 weeks.
Non-inferiority was tested by comparing pairwise differences in
retention rates using a multiple testing procedure to adjust for
multiplicity and a confidence interval approach with a pre-defined
non-inferiority margin of -0.1. Secondary variables included effi-
cacy using patient’s assessment of OA pain intensity in the target
joint, patient’s and physician’s global assessment of disease ac-
tivity (defined as improvement by at least one grade in the Likert
scale), usage of rescue medication and safety and tolerability.
Results: Patient disposition was similar across the treatment
groups. Approximately 45% of patients in each group remained
on treatment until study end. An amendment to the protocol
following the announcement of possible increased CV risk with
celecoxib excluded patients with CCV history and elevated CV
risk (13%) and led to withdrawal of consent in 4% of the patients.
Other major reasons for discontinuations were adverse events
(12%), unsatisfactory therapeutic effect (11%) and withdrawal of
consent (7%).
The results of the retention to treatment analysis are shown in
Table 1.
Comparisons using an integrated measure of the overall level
of OA pain intensity and patient’s and physician’s global as-
sessments of disease activity showed no statistical significant
differences between treatment groups.
Improvement rates at study end for OA pain intensity (51 - 54%),
patient’s and physican’s global assessment and use of rescue
medication were comparable between the treatment goups.
The safety and tolerability of both lumiracoxib doses and cele-
coxib were generally similar, with comparable overall incidences
of AEs and SAEs. APTC events (stroke, MI, CV death) occurred
in similar rates (0.7-0.8%). ALT/AST elevations > 3 x ULN oc-
curred at a higher frequency in patients treated with lumiracoxib
100 mg bid (2x recommended dose) than with lumiracoxib 100
mg od or celecoxib 200 mg od.
Conclusions: Retention on treatment at 1 year of lumiracoxib
100mg od was non-inferior to celecoxib 200 mg od and all
secondary efficacy parameters were comparable between these
treatment groups. Lumiracoxib 100 mg od was shown to be as
effective and safe as celecoxib 200 mg od.
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Purpose: This trial is a prospective assessment of the effi-
cacy and tolerability of intra-articular sodium hyaluronate (SH;
